231 related articles for article (PubMed ID: 18669715)
21. Elevated maternal second-trimester serum alpha-fetoprotein as a risk factor for placental abruption.
Tikkanen M; Hämäläinen E; Nuutila M; Paavonen J; Ylikorkala O; Hiilesmaa V
Prenat Diagn; 2007 Mar; 27(3):240-3. PubMed ID: 17238224
[TBL] [Abstract][Full Text] [Related]
22. Second trimester serum markers.
Canick JA; MacRae AR
Semin Perinatol; 2005 Aug; 29(4):203-8. PubMed ID: 16104669
[TBL] [Abstract][Full Text] [Related]
23. Maternal serum screening for trisomy 21 in women with a false positive result in last pregnancy.
Abdul-Hamid S; Fox R; Martin I
J Obstet Gynaecol; 2004 Jun; 24(4):374-6. PubMed ID: 15203574
[TBL] [Abstract][Full Text] [Related]
24. The association of triple-marker test results with adverse pregnancy outcomes in low-risk pregnancies with healthy newborns.
Sayin NC; Canda MT; Ahmet N; Arda S; Süt N; Varol FG
Arch Gynecol Obstet; 2008 Jan; 277(1):47-53. PubMed ID: 17653738
[TBL] [Abstract][Full Text] [Related]
25. First trimester screening for Down syndrome in rhesus negative women.
Muhcu M; Mungen E; Atay V; Ipcioglu OM; Dundar O; Ergur R; Yergok YZ
Prenat Diagn; 2008 May; 28(5):404-7. PubMed ID: 18318000
[TBL] [Abstract][Full Text] [Related]
26. First-trimester screening for trisomy 21 by free beta-human chorionic gonadotropin and pregnancy-associated plasma protein-A: impact of maternal and pregnancy characteristics.
Kagan KO; Wright D; Spencer K; Molina FS; Nicolaides KH
Ultrasound Obstet Gynecol; 2008 May; 31(5):493-502. PubMed ID: 18432600
[TBL] [Abstract][Full Text] [Related]
27. The influence of maternal opiate use in pregnancy on second trimester biochemical markers for Down syndrome.
Scott GJ; Holding S; Purcell A; Tutty S; Lindow SW
Prenat Diagn; 2009 Sep; 29(9):863-5. PubMed ID: 19488976
[TBL] [Abstract][Full Text] [Related]
28. Reliability of second trimester triple screening for Down syndrome in rhesus-negative women.
Muhcu M; Mungen E; Dundar O; Bodur S; Tutuncu L; Atay V; Ozcan O; Yergok YZ
J Perinatol; 2007 May; 27(5):268-71. PubMed ID: 17363912
[TBL] [Abstract][Full Text] [Related]
29. Serum vitamin A and beta-carotene levels in pregnant women infected with human immunodeficiency virus-1.
Phuapradit W; Chaturachinda K; Taneepanichskul S; Sirivarasry J; Khupulsup K; Lerdvuthisopon N
Obstet Gynecol; 1996 Apr; 87(4):564-7. PubMed ID: 8602309
[TBL] [Abstract][Full Text] [Related]
30. Early invasive diagnostic techniques in pregnant women who are infected with the HIV: a multicenter case series.
Somigliana E; Bucceri AM; Tibaldi C; Alberico S; Ravizza M; Savasi V; Marini S; Matrone R; Pardi G;
Am J Obstet Gynecol; 2005 Aug; 193(2):437-42. PubMed ID: 16098867
[TBL] [Abstract][Full Text] [Related]
31. Lack of correlation between elevated maternal serum hCG during second-trimester biochemical screening and fetal congenital anomaly.
Celentano C; Guanciali-Franchi PE; Liberati M; Palka C; Fantasia D; Morizio E; Calabrese G; Stuppia L; Rotmensch S
Prenat Diagn; 2005 Mar; 25(3):220-4. PubMed ID: 15791663
[TBL] [Abstract][Full Text] [Related]
32. Elevated maternal midtrimester serum free beta-human chorionic gonadotropin levels in vegetarian pregnancies that cause increased false-positive Down syndrome screening results.
Cheng PJ; Chu DC; Chueh HY; See LC; Chang HC; Weng DR
Am J Obstet Gynecol; 2004 Feb; 190(2):442-7. PubMed ID: 14981387
[TBL] [Abstract][Full Text] [Related]
33. Pregnancies conceived using assisted reproductive technologies (ART) have low levels of pregnancy-associated plasma protein-A (PAPP-A) leading to a high rate of false-positive results in first trimester screening for Down syndrome.
Amor DJ; Xu JX; Halliday JL; Francis I; Healy DL; Breheny S; Baker HW; Jaques AM
Hum Reprod; 2009 Jun; 24(6):1330-8. PubMed ID: 19246467
[TBL] [Abstract][Full Text] [Related]
34. Maternal serum alpha-fetoprotein and human chorionic gonadotropin levels in women with human immunodeficiency virus.
Gross S; Castillo W; Crane M; Espinosa B; Carter S; DeVeaux R; Salafia C
Am J Obstet Gynecol; 2003 Apr; 188(4):1052-6. PubMed ID: 12712109
[TBL] [Abstract][Full Text] [Related]
35. [Specificity of biochemical markers of pregnancy second trimester].
Salazar López R; Ibarra Gallardo AL; Iduma Meléndrez M; Leyva Bojórquez R
Ginecol Obstet Mex; 2007 Oct; 75(10):608-14. PubMed ID: 18800579
[TBL] [Abstract][Full Text] [Related]
36. First- and second-trimester evaluation of risk for Down syndrome.
Ball RH; Caughey AB; Malone FD; Nyberg DA; Comstock CH; Saade GR; Berkowitz RL; Gross SJ; Dugoff L; Craigo SD; Timor-Tritsch IE; Carr SR; Wolfe HM; Emig D; D'Alton ME;
Obstet Gynecol; 2007 Jul; 110(1):10-7. PubMed ID: 17601890
[TBL] [Abstract][Full Text] [Related]
37. Second-trimester Down syndrome maternal serum marker screening: a prospective study of 11 040 twin pregnancies.
Garchet-Beaudron A; Dreux S; Leporrier N; Oury JF; Muller F; ;
Prenat Diagn; 2008 Dec; 28(12):1105-9. PubMed ID: 19003979
[TBL] [Abstract][Full Text] [Related]
38. Preliminary estimate for the second-trimester maternal serum screening detection rate of the 45,X karyotype using alpha-fetoprotein, unconjugated estriol and human chorionic gonadotropin.
Benn PA; Ying J
J Matern Fetal Neonatal Med; 2004 Mar; 15(3):160-6. PubMed ID: 15280141
[TBL] [Abstract][Full Text] [Related]
39. Second-trimester maternal serum screening for Down syndrome in Mainland China.
Liao C; Huang Y; Li D; Song S; Yi C; Zhou J
Prenat Diagn; 2006 Dec; 26(13):1271-2. PubMed ID: 17139699
[No Abstract] [Full Text] [Related]
40. The HELLP syndrome: its association with unexplained elevation of MSAFP and MShCG in the second trimester.
Morssink LP; Heringa MP; Beekhuis JR; De Wolf BT; Mantingh A
Prenat Diagn; 1997 Jul; 17(7):601-6. PubMed ID: 9249859
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
